Fluorodeoxyglucose positron emission tomography in Richardson's syndrome and progressive supranuclear palsy-parkinsonism

Movement Disorders

Volumn 27, Issue 1, 2012, Pages 151-155

  Srulijes, Karin ^a,b   Reimold, Matthias ^b   Liscic, Rajka M ^a,b   Bauer, Sarah ^a,b   Dietzel, Elisabeth ^a,b   Liepelt Scarfone, Inga ^a,b   Berg, Daniela ^a,b   Maetzler, Walter ^a,b,c  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c ROBERT BOSCH HOSPITAL   (Germany)

Author keywords

Hypometabolism; Parkinsonism; Positron emission tomography; Postural instability; Progressive supranuclear palsy

Indexed keywords

FLUORODEOXYGLUCOSE;

ARTICLE; BODY EQUILIBRIUM; BRAIN METABOLISM; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; FRONTAL CORTEX; HUMAN; PARKINSON DISEASE; PARKINSONISM; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; PROGRESSIVE SUPRANUCLEAR PALSY PARKINSONISM; PUTAMEN; RICHARDSON SYNDROME; THALAMUS; UNIFIED PARKINSON DISEASE RATING SCALE;

AGED; BRAIN; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY; PUTAMEN; ROC CURVE; SEVERITY OF ILLNESS INDEX; SUPRANUCLEAR PALSY, PROGRESSIVE; THALAMUS;

EID: 84855936161     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23975     Document Type: Article

References (25)

1. Williams DR, de Silva R, Paviour DC, et al. Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism. Brain 2005; 128( Pt 6): 1247-1258.
2. Steele JC, Richardson JC, Olszewski J. Progressive supranuclear palsy. a heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch Neurol 1964; 10: 333-359.
3. Richardson JC, Steele J, Olszewski J. Supranuclear ophthalmoplegia, pseudobulbar palsy, nuchal dystonia and dementia. a clinical report on eight cases of "heterogenous system degeneration". Trans Am Neurol Assoc 1963; 88: 25-29.
4. Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 1996; 47: 1-9.
5. Pinkhardt EH, Jurgens R, Becker W, Valdarno F, Ludolph AC, Kassubek J. Differential diagnostic value of eye movement recording in PSP-parkinsonism, Richardson's syndrome, and idiopathic Parkinson's disease. J Neurol 2008; 255: 1916-1925.
6. Jellinger KA. Different tau pathology pattern in two clinical phenotypes of progressive supranuclear palsy. Neurodegener Dis 2008; 5: 339-346.
7. Williams DR, Holton JL, Strand C, et al. Pathological tau burden and distribution distinguishes progressive supranuclear palsy-parkinsonism from Richardson's syndrome. Brain 2007; 130( Pt 6): 1566-1576.
8. Karbe H, Holthoff V, Huber M, et al. Positron emission tomography in degenerative disorders of the dopaminergic system. J Neural Transm 1992; 4: 121-130.
9. Juh R, Kim J, Moon D, Choe B, Suh T. Different metabolic patterns analysis of Parkinsonism on the 18F-FDG PET. Eur J Radiol 2004; 51: 223-233.
10. Teune LK, Bartels AL, de Jong BM, et al. Typical cerebral metabolic patterns in neurodegenerative brain diseases. Mov Disord 2010; 25: 2395-2404.
11. Eckert T, Barnes A, Dhawan V, et al. FDG PET in the differential diagnosis of parkinsonian disorders. Neuroimage 2005; 26: 912-921.
12. Bohnen NI, Muller ML, Koeppe RA, et al. History of falls in Parkinson disease is associated with reduced cholinergic activity. Neurology 2009; 73: 1670-1676.
13. Hirano S, Shinotoh H, Shimada H, et al. Cholinergic imaging in corticobasal syndrome, progressive supranuclear palsy and frontotemporal dementia. Brain 2010; 133( Pt 7): 2058-2068.
14. Herholz K, Bauer B, Wienhard K, et al. In-vivo measurements of regional acetylcholine esterase activity in degenerative dementia: comparison with blood flow and glucose metabolism. J Neural Transm 2000; 107: 1457-1468.
15. Zwergal A, la Fougere C, Lorenzl S, et al. Postural imbalance and falls in PSP correlate with functional pathology of the thalamus. Neurology 2011; 77: 101-109.
16. Lozza C, Baron JC, Eidelberg D, Mentis MJ, Carbon M, Marie RM. Executive processes in Parkinson's disease: FDG-PET and network analysis. Hum Brain Mapp 2004; 22: 236-245.
17. Srulijes K, Mallien G, Bauer S, et al. In vivo comparison of Richardson's syndrome and progressive supranuclear palsy-parkinsonism. J Neural Transm 2011; 118: 1191-1197.
18. Agosta F, Kostic VS, Galantucci S, et al. The in vivo distribution of brain tissue loss in Richardson's syndrome and PSP-parkinsonism: a VBM-DARTEL study. Eur J Neurosci 2010; 32: 640-647.
19. Fahn S, Elton RL; Committee MotUD. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, eds. Recent developments in Parkinson's disease. New York: MacMillan Health Care Information; 1987: 153-164.
20. Golbe LI, Ohman-Strickland PA. A clinical rating scale for progressive supranuclear palsy. Brain 2007; 130( Pt 6): 1552-1565.
21. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55: 181-184.
22. Liepelt I, Reimold M, Maetzler W, et al. Cortical hypometabolism assessed by a metabolic ratio in Parkinson's disease primarily reflects cognitive deterioration-[18F]FDG-PET. Mov Disord 2009; 24: 1504-1511.
23. Maetzler W, Liepelt I, Reimold M, et al. Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics. Neurobiol Dis 2009; 34: 107-112.
24. Maetzler W, Reimold M, Liepelt I, et al. [(11)C]PIB binding in Parkinson's disease dementia. Neuroimage 2008; 39: 1027-1033.
25. Williams DR, Lees AJ. Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges. Lancet Neurol 2009; 8: 270-279.